Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of Reconciliation of Adjusted EBITDA to Net Loss

The following table presents our revenue, significant expenses reviewed by our CODM and net loss attributable to common shareholders of Evolent Health Inc. (in thousands):


	For the Year Ended December 31,
		2024		2023		2022
Revenue		$2,554,741		$1,963,896		$1,352,013
Less:
Medical expense and device costs		1,813,052		1,143,499		725,036
Cost of revenue excluding medical expense and device costs and other segment items (1)		369,754		358,265		304,326
Selling, general and administrative expenses excluding other segment items (2)		211,475		267,454		216,320
Depreciation and amortization expenses		118,370		123,415		67,195
Interest income		(5,544)		(5,256)		(1,369)
Interest expense		24,722		54,205		15,572
(Gain) loss from equity method investees		3,441		(1,290)		(4,569)
Benefit from income taxes		(1,413)		(89,365)		(43,376)
Change in tax receivables agreement liability		173		61,982		45,950
Other segment items (3)		114,165		193,247		46,092
Net loss attributable to common shareholders of Evolent Health, Inc.		$	(93,454)	$	(142,260)	$	(19,164)

————————

(1)Other segment items excluded from cost of revenue excluding medical expense and device costs include $4.6 million, $1.7 million and $4.4 million of stock compensation for the years ended December 31, 2024, 2023 and 2022, respectively, and $1.6 million of acquisition-related costs and $0.1 million of amortization of contract cost assets for the year ended December 31, 2022.

(2)Other segment items excluded from selling, general and administrative expenses includes $35.2 million, $38.8 million and $29.6 million of stock compensation, $2.9 million, $1.5 million and $13.3 million of severance costs, $2.9 million, $15.1 million and $10.1 million of acquisition-related costs and $10.6 million, $35.2 million and $— million of repositioning costs for the years ended December 31, 2024, 2023 and 2022, respectively.

(3)Other segment items are defined as stock-based compensation, severance costs, acquisition-related costs and repositioning costs not included in cost of revenue or selling, general and administrative expenses and income (expense) calculated in accordance with GAAP including loss on disposal of non-strategic assets, right-of-use assets impairment, loss on lease termination, change in fair value of contingent consideration, loss on extinguishment/repayment of long-term debt, net, other income (expense), net, loss from discontinued operations, net of tax and loss before preferred dividends and accretion of Series A Preferred Stock. Management believes cost of revenue excluding medical expense and device costs and other segment items and selling, general and administrative expenses excluding other segment items are useful to investors because they facilitate an understanding of our long-term operational costs while removing the effect of costs that are not a representative component of the day-to-day operating performance of our business, and are useful to management as supplemental performance measures.